NASDAQ:CLGN CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis $3.74 +0.06 (+1.63%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About CollPlant Biotechnologies Stock (NASDAQ:CLGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CLGN alerts:Sign Up Key Stats Today's Range$3.64▼$3.7550-Day Range$3.74▼$5.4552-Week Range$3.64▼$6.99Volume2,795 shsAverage Volume9,552 shsMarket Capitalization$42.84 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingStrong Buy Company OverviewCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. CollPlant Biotechnologies Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks40th Percentile Overall ScoreCLGN MarketRank™: CollPlant Biotechnologies scored higher than 40% of companies evaluated by MarketBeat, and ranked 684th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingCollPlant Biotechnologies has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCollPlant Biotechnologies has only been the subject of 2 research reports in the past 90 days.Read more about CollPlant Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.44) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CollPlant Biotechnologies is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CollPlant Biotechnologies is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCollPlant Biotechnologies has a P/B Ratio of 1.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CollPlant Biotechnologies' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.18% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 79.01%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCollPlant Biotechnologies does not currently pay a dividend.Dividend GrowthCollPlant Biotechnologies does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.18% of the float of CollPlant Biotechnologies has been sold short.Short Interest Ratio / Days to CoverCollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CollPlant Biotechnologies has recently increased by 79.01%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.60% of the stock of CollPlant Biotechnologies is held by insiders.Percentage Held by InstitutionsOnly 21.69% of the stock of CollPlant Biotechnologies is held by institutions.Read more about CollPlant Biotechnologies' insider trading history. Receive CLGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address CLGN Stock News HeadlinesCollPlant Biotechnologies (NASDAQ:CLGN) Stock Quotes, Forecast and News SummaryOctober 13, 2024 | benzinga.comCollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call TranscriptAugust 21, 2024 | seekingalpha.comCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!November 2, 2024 | Crypto 101 Media (Ad)Cracking The Code: Understanding Analyst Reviews For CollPlant BiotechnologiesAugust 21, 2024 | benzinga.comCollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q2 2024 Earnings Call TranscriptAugust 21, 2024 | msn.comCollPlant Biotechnologies Posts Loss In Q2 - Quick FactsAugust 20, 2024 | markets.businessinsider.comEven after rising 10% this past week, CollPlant Biotechnologies (NASDAQ:CLGN) shareholders are still down 71% over the past three yearsAugust 20, 2024 | finance.yahoo.comCOLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATEAugust 20, 2024 | prnewswire.comSee More Headlines CLGN Stock Analysis - Frequently Asked Questions How have CLGN shares performed this year? CollPlant Biotechnologies' stock was trading at $6.39 at the beginning of 2024. Since then, CLGN stock has decreased by 41.3% and is now trading at $3.75. View the best growth stocks for 2024 here. How were CollPlant Biotechnologies' earnings last quarter? CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) announced its quarterly earnings data on Tuesday, August, 20th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.02. The firm earned $0.25 million during the quarter, compared to analysts' expectations of $0.70 million. CollPlant Biotechnologies had a negative net margin of 2,535.70% and a negative trailing twelve-month return on equity of 65.98%. When did CollPlant Biotechnologies IPO? CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager. Who are CollPlant Biotechnologies' major shareholders? CollPlant Biotechnologies' top institutional investors include Villere ST Denis J & Co. LLC (4.23%) and Pinnacle Associates Ltd. (4.09%). How do I buy shares of CollPlant Biotechnologies? Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CollPlant Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that CollPlant Biotechnologies investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Globant (GLOB), Luminar Technologies (LAZR) and Saia (SAIA). Company Calendar Last Earnings8/20/2024Today11/02/2024Next Earnings (Estimated)12/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:CLGN CUSIPN/A CIK1631487 Webwww.collplant.com Phone972732325600Fax972-73-232-5602Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+193.3%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,020,000.00 Net Margins-2,535.70% Pretax Margin-2,535.70% Return on Equity-65.98% Return on Assets-54.37% Debt Debt-to-Equity RatioN/A Current Ratio6.27 Quick Ratio6.14 Sales & Book Value Annual Sales$689,000.00 Price / Sales62.35 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book1.52Miscellaneous Outstanding Shares11,455,000Free Float10,355,000Market Cap$42.96 million OptionableOptionable Beta0.31 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:CLGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CollPlant Biotechnologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share CollPlant Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.